erlotinib hydrochloride has been researched along with abemaciclib in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (abemaciclib) | Trials (abemaciclib) | Recent Studies (post-2010) (abemaciclib) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 352 | 43 | 343 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | abemaciclib (IC50) |
|---|---|---|---|
| Cyclin-T1 | Homo sapiens (human) | 0.0734 | |
| Cyclin-K | Homo sapiens (human) | 0.065 | |
| Cyclin-dependent kinase 1 | Homo sapiens (human) | 0.7586 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 6.62 | |
| Cyclin-dependent kinase 4 | Homo sapiens (human) | 0.0097 | |
| G2/mitotic-specific cyclin-B1 | Homo sapiens (human) | 0.7484 | |
| Cyclin-A2 | Homo sapiens (human) | 0.1036 | |
| G1/S-specific cyclin-D1 | Homo sapiens (human) | 0.0048 | |
| G1/S-specific cyclin-E1 | Homo sapiens (human) | 0.232 | |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | 0.1847 | |
| G1/S-specific cyclin-D3 | Homo sapiens (human) | 0.0112 | |
| Cyclin-dependent kinase 7 | Homo sapiens (human) | 2.027 | |
| Cyclin-dependent kinase 9 | Homo sapiens (human) | 0.0693 | |
| Cyclin-H | Homo sapiens (human) | 2.6027 | |
| CDK-activating kinase assembly factor MAT1 | Homo sapiens (human) | 3.106 | |
| Cyclin-dependent kinase 6 | Homo sapiens (human) | 0.0168 | |
| Cyclin-dependent-like kinase 5 | Homo sapiens (human) | 0.405 | |
| Cyclin-dependent kinase 5 activator 1 | Homo sapiens (human) | 0.405 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Goldman, JW; Hurt, KC; Koustenis, A; Paz-Ares, L; Reck, M; Shi, P | 1 |
1 trial(s) available for erlotinib hydrochloride and abemaciclib
| Article | Year |
|---|---|
Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non-Small-Cell Lung Cancer With a Detectable KRAS Mutati
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Palliative Care; Prognosis; Proto-Oncogene Proteins p21(ras); Salvage Therapy; Survival Rate; Young Adult | 2016 |